AGENDA & LEARNING OBJECTIVES. Schedule Speaker & Topic Learning Objective(s)

Transcription

1 30 th Annual Alzheimer s Disease Management and Research Symposium Thursday, June 23- Friday, June 24, :30 AM 4:30 PM The Clayton for the Arts, Maryville College Maryville, TN AGENDA & LEARNING OBJECTIVES Schedule Speaker & Topic Learning Objective(s) Thursday, June 23 rd As a result of participating in this activity, the attendee will 7:30 AM 8:30 AM Breakfast and Registration (Exhibitors available) 8:30 AM 8:45 AM Welcome and Introductions Janice Wade Whitehead Executive Director, Alzheimer s Tennessee, Inc. 8:45 AM 10:15 AM Primary Progressive Aphasia Classification and Intervention H. Isabel Hubbard, Ph.D., CCC-SLP University of California San Francisco Memory and Aging San Francisco, CA 10:15 AM 10:35 AM Break (Exhibitors available) Describe the hallmark characteristics of the 3 variants of primary progressive aphasia (PPA) Describe current speechlanguage interventions for the 3 variants of PPA Discuss associated brain regions that are implicated in the 3 variants of PPA Discuss the emerging importance of speechlanguage interventions for primary progressive aphasia

2 10:35 AM 11:30 AM Pharmacological Management of Alzheimer s Disease: The Good, The Bad, and the Ugly Glen E. Farr, Pharm.D. University of Tennessee College of Pharmacy 11:30 AM Noon Alzheimer s Disease and Driving: It s Time to Talk! Nicole White, OTR/L Patricia Neal Rehabilitation Compare and contrast acetylcholinesterase inhibitors used in the pharmacological management of Alzheimer s Describe how the neuropeptide-modifying agent memantine is used in the pharmacological management of Alzheimer s Evaluate the safety and efficacy of medical foods such as caprylidene, cerefolin, and coconut oil in the treatment of Alzheimer s Differentiate the pros and cons of other pharmacological therapies used in, including antipsychotics, monoamine oxidase inhibitors (MAOIs), nicotine, marijuana, ginkgo, aspirin and NSAIDS, vitamins E and D, antioxidants, Omega-3 supplements and other brain health supplements Recognize warning signs for drivers with Alzheimer s Disease or dementia Plan a discussion regarding driving with Alzheimer s Disease or dementia Develop alternative transportation options for successful community mobility Noon 1:00 PM Lunch in Registration Area

3 1:00 PM 2:30 PM Lessons in Giving and Living with the Diagnosis: A Panel Discussion Brenda Nicholson, M.D. Retired physician David R. Compton, M.D. Retired physician Powell, TN Understand the benefits of disclosing the diagnosis of Alzheimer s Disease to patients Implement the SPIKES protocol used to deliver bad news to patients Janice Wade Whitehead Executive Director Alzheimer s Tennessee, Inc. 2:30 PM 2:45 PM Break (Exhibitors available) 2:45 PM 4:00 PM The Collaboration Between Person with the Diagnosis, Physician, and Attorney Kelly G. Frere, CELA Guyton & Frere Lenoir City, TN 4:00 PM 4:15 PM Wrap-up and Evaluation Identify legal advance directives Distinguish the use of certain legal documents Distinguish the difference between law and myth as concerns advance directives Friday, June 24 th 7:30 AM 8:30 AM Breakfast and Registration (Exhibitors available) 8:30 AM 8:45 AM Welcome and Introductions Janice Wade-Whitehead Executive Director, Alzheimer s Tennessee, Inc. 8:45 AM 10:15 AM Research Highlights in Alzheimer s Disease Sanders Brown on Aging University of Kentucky Identify key targets for modification in Discuss genetic influences on with family members of those affected Discuss research participation with interested persons at risk for or with

4 10:15 AM 10:35 AM Break (Exhibitors available) 10:35 AM 11:15 AM Mild Cognitive Impairment Cole Neuroscience, The 11:15 AM - Noon Frontotemporal Dementia: Signs, Symptoms, and Diagnosis Noon 12:45 PM Cole Neuroscience, The Lunch in Registration Area 12:45 PM 2:00 PM Vascular Dementia Sanders Brown on Aging, University of Kentucky Recognize cognitive changes in normal aging Identify risk factors for and subtypes of Mild Cognitive Impairment (MCI) Recognize the symptoms of Frontotemporal Dementia (FTD) Diagnose FTD in a primary care setting Understand the subtypes of FTD See what advancement gaps need to be filled with future work Evaluate cardiovascular risks for dementia in our area Discuss vascular contributions to dementia for those who do not have a history of stroke Identify the specific clinical features of vascular dementia and differentiate them from those seen in Select appropriate treatments for persons suffering from vascular cognitive impairment or dementia 2:00 PM 2:20 PM Break (Exhibitors available)

5 2:20 PM 3:15 PM Dementia in Parkinson s Disease Michelle Lanter Brewer, M.D. Cole Neuroscience, The Describe the relationship between Alzheimer s and Vascular Cognitive Impairment Explain what is meant by vascular contributions to cognitive impairment and dementia (or VCID) Explain how VCID can be modeled in mice and how this might lead to future therapies 3:15 PM 4:15 PM Panel Discussion 4:15 PM 4:30 PM Wrap-up and Evaluation Sanders Brown on Aging, University of Kentucky Cole Neuroscience, The Knoxville,TN Michelle Lanter Brewer, M.D. Cole Neuroscience, The